

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Nikolay Khanzhin, et al. Confirmation No. 1600
Application No.: 10/550,448 Group Art Unit: 1626
Filing or 371(c) Date: November 16, 2005 Examiner: Joseph R. Kosack
For: SUBSTITUTED P-DIAMINO BENZENE DERIVATIVES

Date: **March 8, 2007**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Information Disclosure Statement by Applicant form (PTO/SB/08b).

This Information Disclosure Statement is being filed before the mailing of a first Office action on the merits. Accordingly, neither a fee nor Statement under 37 C.F.R. § 1.97(e) is due. However, if a first Office Action has been mailed, authorization is given to charge the fee under 37 C.F.R. § 1.17(p) (\$180) to Deposit Account No. 50-3201.

Applicants hereby submit a copy of an International Search Report (ISR) (attached) mailed by the International Searching Authority in connection with corresponding Singaporean Patent Application No. 200505972-0 on November 24, 2006. Applicants point out that page 3 of the ISR indicates that GREHN, L., et al., "Selective cathodic cleavage of protected, mixed primary-secondary amines" (attached) is relevant to claims 1-3, 7, 10-12, 18 of the corresponding Singaporean Application under category "X".

Applicants note that page 3 of the ISR further indicates that MARTINELLI, J.E., et al., "Methotrexate analogs. 12. Synthesis and biological properties of some aza homologs" (attached) is relevant to claims 1-7, 10-29 of the corresponding Singaporean Application under category "A".

It is respectfully requested that the above information be considered by the Examiner and that initialed copies of the accompanying Information Disclosure Statement by Applicant form (PTO/SB/08b) be returned to the undersigned indicating that such information has been considered.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee is deemed necessary in connection with filing this Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge this fee to Deposit Account Number 50-3201.

Respectfully submitted,



Stephen G. Kalinchak
Reg. No. 38,747
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
Tel: 201-350-0781
Fax: 201-225-9571